tbuckley/cabot-search huggingface dataset:
Genomic Landscape Established by Allelic Imbalance in the Cancerization Field of a Normal Appearing Airway
Authors: Yasminka Jakubek, Wenhua Lang, Selina Vattathil, Melinda Garcia, Li Xu, Lili Huang, Suk-Young Yoo, Li Shen, Wei Lu, Chi-Wan Chow, Zachary Weber, Gareth Davies, Jing Huang, Carmen Behrens, Neda Kalhor, Cesar Moran, Junya Fujimoto, Reza Mehran, Randa El-Zein, Stephen G. Swisher, Jing Wang, Jerry Fowler, Avrum E. Spira, Erik A. Ehli, Ignacio I. Wistuba, Paul Scheet, Humam Kadara
Journal: Cancer Research (2016)

Abstract Visually normal cells adjacent to, and extending from, tumors of the lung may carry molecular alterations characteristics of the tumor itself, an effect referred to as airway field of cancerization. This airway field has been postulated as a model for early events in lung cancer pathogenesis. Yet the genomic landscape of somatically acquired molecular alterations in airway epithelia of lung cancer patients has remained unknown. To begin to fill this void, we sought to comprehensively characterize the genomic architecture of chromosomal alterations inducing allelic imbalance (AI) in the airway field of the most common type of lung tumors, non–small cell lung cancer (NSCLC). To do so, we conducted a genome-wide survey of multiple spatially distributed normal-appearing airways, multiregion tumor specimens, and uninvolved normal tissues or blood from 45 patients with early-stage NSCLC. We detected alterations in airway epithelia from 22 patients, with an increased frequency in NSCLCs of squamous histology. Our data also indicated a spatial gradient of AI in samples at closer proximity to the NSCLC. Chromosome 9 displayed the highest levels of AI and comprised recurrent independent events. Furthermore, the airway field AI included oncogenic gains and tumor suppressor losses in known NSCLC drivers. Our results demonstrate that genome-wide AI is common in the airway field of cancerization, providing insights into early events in the pathogenesis of NSCLC that may comprise targets for early treatment and chemoprevention. Cancer Res; 76(13); 3676–83. ©2016 AACR.
Clinical trials for T/NK-cell lymphomas in Japan
Authors: Kensei Tobinai
Journal: Annals of Oncology (2015)

The recent clinical trials for T-cell malignancies in Japan will be summarized, focusing on ATL and extranodal NK/T-cell lymphoma (NKTCL). ATL, usually occurs as advanced disease most frequently in Japan, and NKTCL usually occurs as localized disease more frequently in East Asia. Their prognoses were the worst among various peripheral T-cell lymphomas (PTCLs). Japan Clinical Oncology Group (JCOG) has conducted clinical trials to improve their unfavorable outcomes. For aggressive ATL, intensive chemotherapy like VCAP-AMP-VECP is recommended based on the phase III study, JCOG9801 (JCO 2007;25:5458). JCOG is currently conducting a phase II trial of VCAP-AMP-VECP followed by allogeneic SCT (JCOG0907). To facilitate patient enrolment, protocol amendment incorporating mogamulizumab and reduced intensity SCT was made. For indolent ATL, to confirm the promising results of a meta-analysis of zidovudine and interferon alpha, JCOG initiated a phase III study to evaluate the combination comparing with watchful wait (JCOG1111). Patient enrolment into the initial feasibility phase has been completed. For localized NKTCL, concurrent chemoradiotherapy has shown promising efficacy by the phase I/II study, JCOG0211 (JCO 2009;27:5594 / JCO 2012;30:4044). Among various new agents under evaluation for PTCLs, mogamulizumab, a humanized anti-CCR4 antibody engineered to exert potent ADCC by defucosylation, has shown its promising efficacy for relapsed ATL (JCO 2010;28:1591 / JCO 2012;30:837). A subsequent phase II study of mogamulizumab for relapsed PTCL/CTCL has also shown promising efficacy (JCO 2014;32:1157). These results have led to the approval for ATL, PTCL and CTCL in Japan. Among other new agents targeting ATL and PTCL, lenalidomide has shown its promising efficacy for ATL in phase I and II studies (ASH 2012;120:2737).
Breast Carcinoma with Distant Metastasis at Initial Presentation: Impact of Breast Surgery in Real-Life Clinical Practice
Authors: I.J. Dias, A.S.J. Patrão, J. Savva-Bordalo, A. Simas, A.F. Carneiro, A.C. Teixeira, L. Antunes, M.I.R. Ferreira, D. Pereira, N. Afonso
Journal: Annals of Oncology (2014)
Crescendos and Decrescendos: Gastric and Esophageal Cancers
Authors: Jaffer A. Ajani
Journal: Journal of the National Comprehensive Cancer Network (2011)

and Chair of the NCCN Clinical Practice Guidelines in Oncology for Esophageal and Gastric Cancers.He has participated over the past 20 years in numerous trials using innovative combined modality therapies for localized gastric and esophageal cancers, and some of his work has led to the development of strategies of preoperative therapy for resectable upper gastrointestinal cancers.His current research focus is on developing programs to research the molecular markers for progression of Barrett's metaplasia to adenocarcinoma.These research efforts involve multi-institutional collaboration
Abstract A41: The heat shock transcription factor HSF1 induces ovarian cancer epithelial-mesenchymal transition in a 3-D spheroid growth model.
Authors: Trillitye Paullin, Chase Powell, Menzie Christopher, Robert Hill, Christopher Martyniuk, Sandy Westerheide
Journal: Clinical Cancer Research (2016)

Abstract Ovarian cancer is the most lethal gynecological cancer, with over 200,000 women diagnosed each year and over half of those cases leading to death. These poor statistics are related to a lack of early symptoms and inadequate screening techniques. This results in the cancer going undetected until later stages when the tumor has metastasized through a process that requires the epithelial to mesenchymal transition (EMT). In lieu of traditional monolayer cell culture, EMT and cancer progression in general is best characterized through the use of 3D spheroid models. Compared to other cancers, ovarian cancer has very limited treatment options to date, with cisplatin and paclitaxel being the most common and efficient. Recently, a significant increase in heat shock factor 1 (HSF1) expression has been found in highly malignant ovarian cancer. HSF1 is the regulator of the heat shock response (HSR) and promotes the transcription of heat shock proteins (HSPs). Previous studies have shown that HSF1-induced chaperone activity may act to stabilize multiple oncogenes within many different cancer types. This leads to cancer proliferation, reduced apoptosis, and metastasis. In this study, we examine gene expression changes through microarray analysis in spheroid versus monolayer ovarian cancer cells treated with TGFβ to induce EMT. Interestingly, EMT and stress response pathways, including the heat shock response, were all significantly affected by 3D growth. HSF1 knockdown was utilized in both 2D and 3D cultures to further study this response. HSF1 knockdown is shown to inhibit ovarian cancer progression in both monolayer and spheroid model cells. Moreover, HSF1 knockdown in spheroid cells has a significantly greater impact on EMT markers than it does in 2D cultures. This indicates HSF1 may be a utilized as a target for chemotherapeutics in ovarian cancer patients and could potentially have implications in other such hormonal cancers. Citation Format: Trillitye Paullin, Chase Powell, Menzie Christopher, Robert Hill, Christopher Martyniuk, Sandy Westerheide. The heat shock transcription factor HSF1 induces ovarian cancer epithelial-mesenchymal transition in a 3-D spheroid growth model. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research: Exploiting Vulnerabilities; Oct 17-20, 2015; Orlando, FL. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(2 Suppl):Abstract nr A41.
Follow Up On CD8-Depleted Donor-Lymphocyte Infusions After T-Cell Depleted Allogeneic Hemopoietic Stem Cell Transplantation
Authors: Eva Maria Wagner, Daniela Wehler, Timo Schmitt, Aline N. Lay, Karin Kolbe, Matthias Theobald, Wolfgang Herr, Ralf G Meyer
Journal: Blood (2013)
Abstract P1-15-07: The neuroprotective aminopropyl carbazole, P7C3-A20, prevents paclitaxel-induced pain
Authors: PM LoCoco, AL Risinger, SL Mooberry, KA Berg, WP Clarke
Journal: Cancer Research (2016)

Abstract Paclitaxel (PTX), a microtubule-targeting anticancer agent, produces a debilitating peripheral neuropathy that is accompanied by neuropathic pain. Currently, there are only marginally effective therapeutic interventions available. Consequently, patients are forced to reduce or discontinue life-saving chemotherapy to cope with the pain. Recently, a newly identified agent, P7C3-A20, was found to be protective in several models of neurodegeneration, including Parkinson's disease and traumatic brain injury. Given that PTX triggers progressive degeneration of peripheral afferent neurons, this study was performed to evaluate the potential neuroprotective efficacy of P7C3-A20 in rodent models of PTX-induced peripheral neuropathy. P7C3-A20 (10 mg/kg) or vehicle (Cremophor EL/DMSO/5% Dextrose; 1:1:3) was administered intraperitoneally (i.p.) to Sprague-Dawley rats (250-300 g) everyday over a 28-day experimental paradigm. Following two days of treatment with P7C3-A20 or vehicle, rats also received 3 injections of PTX (11.7 mg/kg, i.p.) or vehicle (Cremophor EL/DMSO/5% Dextrose; i.p.) administered every other day. Treatment with P7C3-A20 did not alter body weights or leukocyte counts in control or PTX-treated rats. PTX treatment increased sensitivity to mechanical and cold stimulation (allodynia) of the hindpaw, evidence of peripheral neuropathy. Notably, P7C3-A20 treatment prevented the development of allodynia in response to PTX. Immunohistochemical analysis of paw biopsies indicated that P7C3-A20 prevented PTX-mediated degeneration of terminal nerve endings. Collectively, these data suggest that P7C3-A30 prevented the neurotoxic effects of PTX on peripheral sensory neurons. A xenograft tumor model of triple negative breast cancer was then used to determine whether P7C3-A20 diminished the antitumoral efficacy of PTX. MDA-MB-231 tumors were bilaterally implanted into flanks of female athymic nude mice and allowed to grow for 3 weeks prior to treatment. Using the same treatment protocol as the rats, tumor-bearing mice received daily treatment with P7C3-A20 (20 mg/kg, i.p.) or vehicle for 16 days. P7C3-A20 did not alter PTX-mediated inhibition of tumor growth. Furthermore, P7C3-A20 prevented PTX-induced mechanical allodynia in the mice. Taken together, this work indicates that P7C3-A20 prevents PTX-induced neuropathic damage without diminishing its antitumoral efficacy. P7C3-A20 may be an exciting new candidate to prevent peripheral neuropathy in patients undergoing cancer treatment with PTX. Citation Format: LoCoco PM, Risinger AL, Mooberry SL, Berg KA, Clarke WP. The neuroprotective aminopropyl carbazole, P7C3-A20, prevents paclitaxel-induced pain. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-15-07.
It is time to stratify with prognostic factors for hepatic metastases.
Authors: N J Petrelli
Journal: Journal of Clinical Oncology (1995)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1995.13.9.2471 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 7666107 It is time to stratify with prognostic factors for hepatic metastases. N J PetrellixN J PetrelliSearch for articles by this author https://doi.org/10.1200/JCO.1995.13.9.2471 PDF "It is time to stratify with prognostic factors for hepatic metastases.." Journal of Clinical Oncology, 13(9), pp. 2471–2472© 1995 by American Society of Clinical Oncology
Origins of the fear of success
Authors: J O Cavenar, D S Werman
Journal: American Journal of Psychiatry (1981)

Although neurotic conflicts relating to achievement and success are common among patients in psychoanalysis, the psychoanalytic literature is remarkably limited and tends to portray conflict relating to success only in terms of oedipal conflict. Through four clinical vignettes of patients in psychoanalysis, the authors demonstrate that the fear of success is an overdetermined final common pathway for conflicts at any of several developmental levels.
Acid and Alkaline Phosphatase of Serum and Hepatic Tissue of Rats Fed Carcinogens
Authors: Ambadas S. Mulay, Harlan I. Firminger
Journal: JNCI Journal of the National Cancer Institute (1952)

Journal Article Acid and Alkaline Phosphatase of Serum and Hepatic Tissue of Rats Fed Carcinogens Get access Ambadas S. Mulay, Ambadas S. Mulay Laboratory of Pathology, National Cancer Institute3Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar Harlan I. Firminger Harlan I. Firminger Laboratory of Pathology, National Cancer Institute3Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 12, Issue 4, February 1952, Pages 917–927, https://doi.org/10.1093/jnci/12.4.917 Published: 01 February 1952 Article history Received: 20 November 1951 Published: 01 February 1952
Survivors of imprisonment in the Pacific theater during World War II
Authors: G Goldstein, W van Kammen, C Shelly, D J Miller, D P van Kammen
Journal: American Journal of Psychiatry (1987)

Data were obtained from 41 survivors of imprisonment by the Japanese during World War II. Interview data suggested that these individuals, despite the 40 years that had passed since their prisoner of war experiences, showed manifestations of posttraumatic stress disorder, notably a sleep disturbance marked by recurrent nightmares. MMPI data suggested significant pathology, characterized as an anxiety state, in this group. Half of the subjects met the full set of DSM-III criteria for posttraumatic stress disorder.
Abstract A13: Androgen receptor functions as an adaptor protein for recruitment of protein phosphatase 1a to chromatin and CDK9 mobilization
Authors: Xiaming Liu, Yanfei Gao, Changmeng Cai, Steven Balk, Shaoyong Chen
Journal: Cancer Research (2016)

Abstract The androgen receptor (AR) plays a central role in prostate cancer (PCa) development and progression. AR activity can be modulated by phosphorylation at multiple sites, with S81 phosphorylation mediated by CDK9 playing a particularly important role that may be due to enhancing recruitment of the coactivator p300. The CDK9/cyclin T complex (P-TEFb) is recruited to enhancer/promoter sites by BRD4, where it phosphorylates NELF and RNA polymerase 2 to stimulate transcriptional elongation. A large fraction of P-TEFb is held in an inactive state by association with a 7SK RNA complex, and can be released from this complex through dephosphorylation of CDK9 by protein phosphatase 1 (PP1). The major isoform of the PP1 catalytic subunit, PP1a, associates with a large number of regulatory proteins that target it to specific sites. PNUTS is a regulatory protein targeting PP1a to chromatin, but additional mechanisms that may target PP1a to chromatin to mediate CDK9 dephosphorylation and drive transcriptional elongation remain to be identified. We reported previously that AR could interact with PP1a, and that PP1a could enhance AR activity by dephosphorylating S650 in the AR hinge region and thereby prevent its nuclear export. In this study we show by chromatin immunoprecipitation that AR also recruits PP1a to androgen-stimulated enhancers, and show that PP1a inhibition with tautomycin prevents P-TEFb recruitment to AR-regulated genes and CDK9-mediated phosphorylation of RNA polymerase 2. We further show that PP1a binds to the AR ligand binding domain independently of ligand, and that this binding is negatively regulated by the androgen induced AR N/C-terminal interaction. Significantly, the AR N/C interaction impairs AR recruitment of coactivators prior to chromatin binding, but is disrupted on chromatin to enhance coactivator recruitment, which would also facilitate recruitment of PP1a. These findings indicate that AR functions as a PP1a regulatory protein targeting PP1a to chromatin, and thereby identify a novel mechanism for the selective recruitment of PP1a to a specific subset of genes where it can drive transcriptional elongation, and may also regulate mRNA splicing. Citation Format: Xiaming Liu, Yanfei Gao, Changmeng Cai, Steven Balk, Shaoyong Chen. Androgen receptor functions as an adaptor protein for recruitment of protein phosphatase 1a to chromatin and CDK9 mobilization. [abstract]. In: Proceedings of the AACR Special Conference on Chromatin and Epigenetics in Cancer; Sep 24-27, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2016;76(2 Suppl):Abstract nr A13.
Review: Exercise therapy reduces fatigue in chronic fatigue syndrome
Authors: Michael Denman
Journal: Annals of Internal Medicine (2016)

ACP Journal Club17 May 2016Review: Exercise therapy reduces fatigue in chronic fatigue syndromeMichael Denman, MDMichael Denman, MDImperial College, London, England, UK (M.D.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2016-164-10-055 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationLarun L, Brurberg KG, Odgaard-Jensen J, Price JR. Exercise therapy for chronic fatigue syndrome. Cochrane Database Syst Rev. 2016;2:CD003200. https://pubmed.ncbi.nlm.nih.gov/26852189Clinical Impact RatingsGIM/FP/GP: Rheumatology: Reference1 Smith ME, Haney E, McDonagh M, et al. Treatment of myalgic encephalomyelitis/chronic fatigue syndrome: a systematic review for a National Institutes of Health Pathways to Prevention workshop. Ann Intern Med. 2015;162:841-50. [PMID: 26075755] Google Scholar Author, Article, and Disclosure InformationAffiliations: Imperial College, London, England, UK (M.D.)This article was published at Annals.org on 3 May 2016. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byMechanism of action of Bu Zhong Yi Qi Decoction in the treatment of chronic fatigue syndrome based on network pharmacology and molecular dockingEffect of physical exercise on young anesthesiologists with on-call-related fatigueExercise-induce hyperalgesia, complement system and elastase activation in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome – a secondary analysis of experimental comparative studiesDoes Tai Chi relieve fatigue? A systematic review and meta-analysis of randomized controlled trials 17 May 2016Volume 164, Issue 10Page: JC55KeywordsChronic fatigue syndromeCognitive behavior therapyDrugsExerciseExercise therapyFatigueGrading of Recommendations Assessment Development and EvaluationPhysical functioningSleep ePublished: 17 May 2016 Issue Published: 17 May 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Epidemiology, surveillance and control of infectious diseases in the European overseas countries and territories, 2011
Authors: J Jones, M Gastellu-Etchegorry, F K Stenz, C Baudon, S J Bloem, M Bondonneau, S Cohuet, R Diggle, R W Ewing, I Gerstenbluth, J P Grangeon, K Kumar Alla, G Lajoinie, M Tromp, T Tumahai, J F Yvon, C M Swaan, C M Gossner
Journal: Eurosurveillance (2011)

The 25 European overseas countries and territories (OCTs) are closely associated with the European Union (EU) through the four related UE Member States: Denmark, France, the Netherlands and the United Kingdom. In 2008 and 2009, these four EU Member States, in association with the European Centre for Disease Prevention and Control (ECDC), reviewed the OCTs’ needs, with the objectives of documenting their capacity to prevent and respond to infectious diseases outbreaks, and identifying deficiencies. This Euroroundup is based on the review’s main findings, and presents an overview of the OCTs’ geography and epidemiology, briefly introduces the legal basis on which they are linked to the EU and describes the surveillance and infectious disease response systems. As a result of their diversity the OCTs have heterogeneous epidemiological profiles. A common factor, however, is that the main burden of disease is non-communicable. Nevertheless, OCTs remain vulnerable to infectious diseases outbreaks. Their capacity for surveillance, early detection and response to such outbreaks is generally limited, with laboratory capacity issues and lack of human resources. Avenues for capacity strengthening should be explored by the OCTs and the related EU Member States, in collaboration with ECDC and regional public health networks where these exist.
The Action of Analogues of &lt;sc&gt;dl&lt;/sc&gt;-Glyceraldehyde on Glycolysis and Respiration of Tumors&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Joseph Gold
Journal: JNCI Journal of the National Cancer Institute (1959)

Three analogues of dl-glyceraldehyde were tested on whole cells of various ascites tumors. Glycidaldehyde and α-methoxyhydracrylaldehyde were found to be potent inhibitors of both glycolysis and respiration, while β-methoxylactaldehyde was only weakly inhibitory. The mechanism of action was presumably through the aldolase reaction in which compounds inhibitory to hexokinase were formed, although glycidaldehyde may readily act as an alkylating agent, while β-methoxylactaldehyde may act to rearrange itself to dihydroxyacetone methyl ether. Glycidaldehyde was more strongly inhibitory to glycolysis than to respiration in the lymphoma only, whereas just the reverse was true in the other tumors. This suggests that lymphomas may be different from other cancers. It is speculated that a specific inhibitor to a specific glycolytic enzyme might provide a practical test of the Warburg theory.
Is the recent emergence of mephedrone injecting in the United Kingdom associated with elevated risk behaviours and blood borne virus infection?
Authors: Vivian D Hope, Katelyn J Cullen, Josie Smith, Lucy Jessop, John Parry, Fortune Ncube
Journal: Eurosurveillance (2016)

The recent, and rapid, emergence of injection of the short-acting stimulant mephedrone (4-methylmethcathione) has resulted in concerns about increased infection risks among people who inject drugs (PWID). Data from the bio-behavioural surveillance of PWID in the United Kingdom were analysed to examine the impact of mephedrone injection on infections among PWID. During the year preceding the survey, 8.0% of PWID (163/2,047) had injected mephedrone. In multivariable analyses, those injecting mephedrone were younger, less likely to have injected opiates, and more likely to have injected cocaine or amphetamines, used needle/syringe programmes or sexual health clinics, been recruited in Wales and Northern Ireland or shared needles/syringes. There were no differences in sexual risks. Those injecting mephedrone more often had hepatitis C antibodies (adjusted odds ratio (AOR) = 1.51; 95% confidence interval (CI): 1.08–2.12), human immunodeficiency virus (AOR = 5.43; 95% CI: 1.90–15.5) and overdosed (AOR = 1.70; 95% CI: 1.12–2.57). There were no differences in the frequency of injecting site infections or prevalence of hepatitis B. The elevated levels of risk and infections are a concern considering its recent emergence. Mephedrone injection may currently be focused among higher-risk or more vulnerable groups. Targeted responses are needed to prevent an increase in harm.
TFE3-Expressing Perivascular Epithelioid Cell Neoplasm (PEComa) of the Sella Turcica
Authors: Martin D. Hyrcza, Daniel A. Winer, Mary Shago, Karolyn Au, Gelareh Zadeh, Sylvia L. Asa, Ozgur Mete
Journal: Endocrine Pathology (2016)